StreetAlpha.app
Home › Stocks › RCEL

AVITA Medical, Inc. (RCEL)

Healthcare
$15.77
▲ +3.61%
LAST CLOSE · NOV 17

AVITA Medical sells RECELL, a skin cell device for wound care, plus PermeaDerm and Cohealyx wound matrices to burn and trauma centers. It last closed at $15.77 on Nov 17, up 3.61% on the day. RCEL reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 3 analysts is $21.00 (+33.2% from the last close), with a high of $22.00 and a low of $20.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is RCEL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$84.7M
+17.0% vs a year ago
Net income
−$36.1M
−42.7% margin
EPS (diluted)
−$1.17
Free cash flow
−$20.2M
−23.8% margin
Valuation
Market cap
$495.5M
31.4M shares
P/E
–
No P/E while losing money
Price to sales
5.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.5M
At Sep 30
Debt
$45.5M
At Sep 30
Shareholder equity
−$31.0M
Shares outstanding
31.4M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $29.2M$29.2MFY2021FY2022: $34.4M$34.4MFY2022FY2023: $50.1M$50.1MFY2023FY2024: $64.3M$64.3MFY2024FY2025: $71.6M$71.6MFY2025

From RCEL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
-$0.14
$26.0M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on RCEL in the past 90 days
Average 12-month target
$21.00
▲ 33.2% upside

Based on 3 analysts who set a price target on RCEL in the past 90 days. The average target is $21.00, with a high of $22.00 and a low of $20.00, compared with the last close of $15.77.

Low $20.00Avg $21.00High $22.00
Blue marker: last close $15.77
Highest target$22.00
Average target$21.00
Lowest target$20.00
Latest rating changes
TD CowenTarget raised
Nov 12Buy$14 → $22
Lake StreetTarget raised
Nov 7Buy$12 → $20
BTIGTarget raised
Nov 6Buy$15 → $21
BTIGTarget raised
Oct 12Buy$11 → $15
Lake StreetTarget raised
Aug 28Buy$6 → $12
DateFirmActionRatingPrice target
Nov 12TD CowenTarget raisedBuy$14 → $22
Nov 7Lake StreetTarget raisedBuy$12 → $20
Nov 6BTIGTarget raisedBuy$15 → $21
Oct 12BTIGTarget raisedBuy$11 → $15
Aug 28Lake StreetTarget raisedBuy$6 → $12
Loading…

Technical Analysis

RCEL · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 54% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 54). The nearest support is the Pivot at $15.70, and the nearest resistance the 20 day average at $16.03.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.2%/day
Key levels
$18.4352 week high+16.9%
$16.90Swing high (Oct 29)+7.2%
$16.34Pivot R1+3.6%
$16.0320 day average+1.6%
$15.77Last close
$15.70Pivot−0.4%
$15.13Pivot S1−4.1%
$14.67Swing low (Nov 2)−7.0%
$13.5950 day average−13.8%
$10.20100 day average−35.3%
$7.27200 day average−53.9%
$3.2252 week low−79.6%
Indicators
RSI (14)54.05Middle of its rangeNeutral
MACD0.71Below its signal lineBearish
Stochastic23.1Middle of its rangeNeutral
ADX (14)31.9Trending up
Williams %R-70.7Oversold below −80, overbought above −20Neutral
CCI (20)-32.4Oversold below −100, overbought above 100Neutral
Rate of change+2.9%Change over 10 sessionsBullish
ATR (14)$1.14Typical daily range, 7.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for RCEL

What happened before

See how RCEL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RCEL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RCEL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RCEL in the last 90 days.

Loading…

See today’s whale options flow across the market →

RCEL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲59 buying vs 39 selling
  • ▲Held by funds +13.8 pts
  • ▲Funds holding +16
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8973+21.9%
In funds' top 1000–
Held by funds29.5%15.7%+13.8 pts
New / increased33 / 2620 / 25+31.1%
Reduced / sold out22 / 1720 / 24−11.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RCEL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCEL is in one of them and how their past RCEL trades turned out.

RCEL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RCEL in an article yet. Here's the latest on the wider market.

RCEL Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed May 14
Who traded RCEL · since 2025
Latest 1 filing
$1K – $15KTraded Mar 28, 2025Filed May 14, 2025
PersonTypeAmountTradedFiledDelay
Keith SonderlingExecutive branchSell$1K – $15KMar 28, 2025May 14, 202547 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About AVITA Medical

AVITA Medical is an acute wound care company based in Valencia, California. Its main product is RECELL, a device that lets clinicians prepare a suspension of a patient's own skin cells at the point of care, which can cover large wounds using a small donor skin sample. The company also sells PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a dermal matrix made from collagen. Its customers are mainly burn, trauma and surgical centers, chiefly in the United States.

Headquarters
Valencia, CA
Founded
1993